This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2012 Jan 20;30(3):339; author reply 339-40.

doi: 10.1200/JCO.2011.39.0740. Epub 2011 Dec 19.

p53 status in locally advanced bladder cancer

Omer Dizdar, Umut Demirci

PMID: 22184388
DOI: 10.1200/JCO.2011.39.0740

Comment

p53 status in locally advanced bladder cancer

Omer Dizdar et al. J Clin Oncol. 2012.

. 2012 Jan 20;30(3):339; author reply 339-40.

doi: 10.1200/JCO.2011.39.0740. Epub 2011 Dec 19.

Authors

Omer Dizdar, Umut Demirci

PMID: 22184388
DOI: 10.1200/JCO.2011.39.0740

No abstract available

PubMed Disclaimer

Comment on

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Stadler WM, et al. J Clin Oncol. 2011 Sep 1;29(25):3443-9. doi: 10.1200/JCO.2010.34.4028. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810677 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal